Empiriko is working with CreaGen Biosciences to make its technology that mimics metabolism by liver enzymes more widely available to drug developers. The technology--called Biomimiks--was officially unveiled last month to help R&D teams quickly understand metabolic patterns, pathways and profiles of their drugs. Teaming with drug discovery service provider CreaGen is intended to help Empiriko scale and standardize the predictive technology. Release